Genetic Alterations and clinical record in surgically debulked OVarian cancer patients by Liquid biopsy And whole eXome analYsis - GALAXY-OV trial

ational Cancer Center0 sites150 target enrollmentApril 3, 2023

Conditionsovarian cancer

Overview

Phase: 未知
Intervention: Not specified
Conditions: ovarian cancer
Sponsor: ational Cancer Center
Enrollment: 150
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 3, 2023

End Date

March 31, 2029

Last Updated

2 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

ational Cancer Center

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\.Patients with a history of treatment with PARP inhibitors or bevacizumab. 2\.Patients who plan to use bevacizumab for preoperative adjuvant chemotherapy. 3\.Persons with a history of malignancy(\*6\) (\*6\)Patients with a recurrence\-free period of at least 5 years or with basal or spinous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma equivalent lesions that are considered cured by local treatment may be enrolled. 4\.Persons with active local or systemic infections requiring treatment. 5\.Persons who are HBs antigen positive, HBc antibody positive(\*7\) or HCV antibody positive(\*8\) (\*7\) HBc antibody positive, but HBV\-DNA negative is acceptable for registration. (\*8\) HCV antibody\-positive but HCV\-RNA\-negative patients are eligible for registration. 6\.Must be HIV antibody positive (HIV antibodies may be untested for registration). 7\.Patients with a history of interstitial lung disease requiring treatment (interstitial pneumonia, pulmonary fibrosis, etc.) or extensive findings of these diseases on CT. 8\.Patients with uncontrolled complications(\*8\). (\*8\)Gastrointestinal bleeding, cardiac disease, glaucoma, diabetes, etc. 9\.Patients receiving continuous systemic administration (oral or intravenous) of steroids (prednisolone equivalent of 10 mg/day or more for at least 2 weeks) 10\.Persons who are judged to have difficulty enrolling in this study due to clinically problematic psychiatric disorders. 11\.History of hemoptysis (sputum of 2\.5 mL or more of fresh blood). 12\.Pregnant or lactating women. 13\.Other persons who are deemed by the physician in charge to be unsuitable for enrollment in this study.